K.K. Heriosu
Romanized株式会社 ヘリオス
About this English name
Auto-romanized from the registered Japanese kana reading. Not an officially registered English name.
For sanctions screening or contractual purposes, always cross-reference using the Corporate Number (法人番号) shown above, not the English name.
Enforcement records (2)
- Oct 5, 2017先駆け審査指定制度対象品目の募集薬事法Ministry of Health, Labour and Welfare
Human (same species) adult bone marrow-derived pluripotent precursor cells for acute phase cerebral infarction (18 to 36 hours after onset)
- Feb 28, 2017指定薬事法Ministry of Health, Labour and Welfare
A stem cell product used for the treatment of acute cerebral infarction, derived from adult human (same species) bone marrow multipotent progenitor cells, developed overseas. It is a suspension of adherent stem cells collected and processed from donor bone marrow, with novelty and high breakthrough potential aimed at improving functional impairments caused by acute cerebral infarction.
Watch this company
Get an email when K.K. Heriosu has new enforcement actions or registry changes. Sign-in is via a one-time email link — no password required.
Language
日本語版を見る (Japanese)Registry data
- Status
- Active
For compliance use
This profile aggregates public Japanese government records. Always cross-reference the Corporate Number when matching this entity in your systems — Japanese English company names are often inconsistent across sources.